GlassScriptPhysician profile
Brian Shelley
NPI 1346274453
$5,150.50
in general payments reported to CMS, 2019-2025
14 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.27 · 2020: $78.68 · 2021: $3,720 · 2022: $348 · 2023: $132 · 2024: $449 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,333.33 | 2021 | |
| Alcon Vision LLC | $1,018.81 | 2021-2025 | Clareon, Centurion, Luxor |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.58 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $124.41 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $108.73 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $105.11 | 2025 | Via360, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $95.16 | 2019-2025 | |
| Carl Zeiss Meditec, INC. | $44.90 | 2021 | |
| Bausch & Lomb Americas INC. | $42.65 | 2023-2024 | Envista Mx60 Iol, Miebo |
| Allergan, INC. | $38.12 | 2019-2020 | |
| Abbvie INC. | $33.91 | 2022-2023 | Durysta |
| Ivantis, INC | $28.45 | 2020-2021 | |
| Harrow Eye, LLC | $17.12 | 2025 | |
| Aerie Pharmaceuticals, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.